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Patients with MYC-rearrangement positive large B-cell lymphoma(MYC+ LBCL) have an inferior prognosis following standard first-linetherapy with rituximab, cyclophosphamide, doxorubicin, vincristine,
and prednisolone (R-CHOP) compared to patients without MYC rearrange-
ment. Although intensive chemotherapy regimens yield higher remission
rates, toxicity remains a concern. Lenalidomide is an oral immunomodula-
tory drug which downregulates MYC and its target genes thereby provid-
ing support using lenalidomide as additional therapeutic option for MYC+
LBCL. A phase II trial was conducted evaluating the efficacy of lenalido-
mide (15 mg day 1-14) in combination with R-CHOP (R2CHOP) in newly
diagnosed MYC+ LBCL patients identified through a nationwide MYC-
FISH screening program. The primary endpoint was complete metabolic
response (CMR) on centrally reviewed 18F-fluorodeoxyglucose (18F-FDG)
positron emission tomography (PET)-computer tomography (CT)-scan at
end-of-treatment. Secondary endpoints were overall survival (OS), disease-
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free survival (DFS) and event-free survival (EFS). Eighty-two patients with stage II-IV MYC+ LBCL were treat-
ed with six cycles of R2CHOP. At end of treatment, 67% (95% Confidence interval [CI]: 58-75) of the patients
reached CMR. With a median follow-up of 25.4 months, 2-year estimates for OS, DFS, EFS were 73% (95%
CI: 62-82), 75% (95% CI: 63-84) and 63% change to: (95% CI: 52-73) respectively. In this prospective trial
for newly diagnosed MYC+ LBCL patients, we found that administering R2CHOP was safe, and yields com-
parable CMR and survival rates as in studies applying more intensive chemotherapy regimens. Hence, these
findings offer new prospects for MYC+ LBCL patients and warrant comparison in prospective randomized
clinical trials. This trial was registered at www.clinicaltrialsregister.eu (#2014-002654-39).  
Introduction
Diffuse large B-cell lymphoma (DLBCL) comprises about
35% of all non-Hodgkin lymphomas (NHL) and is the most
common lymphoma subtype.1 The outcome of patients
treated with rituximab, cyclophosphamide, 
doxorubicin, vincristine, and prednisolone (R-CHOP) is het-
erogeneous for which the IPI score and cell-of-origin (COO)
are the most well-known denominators.2,3 MYC rearrange-
ment status is an independent prognostic factor, and is
reported in 10-15% of DLBCL patients (hereafter MYC+
LBCL).4-7 In about 30% of these patients, only a 
single MYC rearrangement is found (single hit [SH]), while
in 70% MYC rearrangement is detected together with
either a BCL2 or BCL6 rearrangement (double hit [DH]:
MYC+/BCL2+ or MYC+/BCL6+) or with both (triple hit
[TH]: MYC+/BCL2+/BCL6+).4 It has been shown that in
patients with MYC+ LBCL, standard first-line therapy with
R-CHOP results in an inferior prognosis compared to those
without MYC rearrangement (2-year OS 35% vs. 61%8 and
5-year OS 31% vs. 66%6). Moreover, patients with MYC+
LBCL have an increased risk of central nervous system
(CNS) relapse.5,6 Recently, Rosenwald et al. demonstrated
that the inferior prognosis of MYC rearranged patients is
however largely observed in patients with DH/TH lym-
phoma.7 In the revised World Helath Organisation (WHO)
2017 classification, SH is not recognized as a separate entity
in contrast to DH/TH lymphoma.1
In search for improvement, intensified chemotherapy
regimens, such as hyper-CVAD and R-CODOX-M/R-
IVAC, have been investigated. Data mainly come from sub-
analyses of MYC rearrangement positive patients in trials
designed for unselected DLBCL patients. These 
studies indicate that intensified treatment results in
improvement of progression free survival (PFS), but not
OS.9-11 Only recently, a prospective, multicenter, single arm
phase II study specifically designed for MYC+ LBCL
patients showed that DA-EPOCH-R resulted in a promising
CMR rate at end of treatment (EOT) of 74% and 4 year EFS
and OS of 71% and 77%, respectively.12 
Lenalidomide is an oral immunomodulatory drug with
direct antitumor effects and indirect effects on the tumor
microenvironment.13 In vitro studies have demonstrated that
lenalidomide exposure results in down-regulation of MYC
and its target genes via cereblon and IRF4 in lymphoid cells,
thereby providing the rationale for introdu-cing lenalido-
mide as a therapeutic option in MYC+ LBCL.14 Two phase
II studies in ABC/non-GCB-subtype DLBCL have demon-
strated that the addition of lenalidomide to R-CHOP
(R2CHOP) is indeed feasible and may contribute to a favor-
able outcome by decreasing CNS relapse.15,16 Against expec-
tation, R2CHOP did not result in a survival advantage in
ABC-subtype DLBCL, as has recently been shown in a
phase III study (ROBUST).17
The present study reports the results of a prospective sin-
gle-arm phase II trial forMYC+ LBCL patients treated with
R2CHOP. Patients were identified through a nationwide
molecular biomarker diagnostics program. We report out-
come based on the primary endpoint, which was CMR by
centrally reviewed a 18F-fluorodeoxyglucose (18F-FDG)
positron emission tomography (PET)-computer tomogra-
phy (CT) scan at EOT, as well as 2-year OS, DFS and EFS
rates. 
Methods
Screening program and patient eligibility
To support timely diagnosis of MYC+ LBCL and optimal enrol-
ment in the present clinical trial, a nationwide diagnostic support
program for MYC rearrangement assessment by fluorescence in
situ hybridization (FISH) was implemented.18 
Patients ≥18 years with newly diagnosed DLBCL or with B-cell
lymphoma, unclassifiable, with features intermediate  between
DLBCL and Burkitt lymphoma (BLC-U) according to the WHO
2008 classification with a proven MYC rearrangement by FISH
analysis including SH (not Burkitt lymphoma), DH or TH DLBCL
were eligible. 
During the screening period one cycle of R-CHOP, a short
course of steroids, or irradiation to control local symptoms was
allowed. Patients with Ann Arbor stage II-IV, a WHO performance
status (PS) of 0-3, ≥ one lesion of ≥1.5 cm on a contrast-enhanced
CT scan and ≥one positive lesion on PET-CT scan were eligible. 
Patients diagnosed with any other subtype of aggressive B-cell
lymphoma, a history of follicular lymphoma, proven CNS local-
ization or HIV positivity were excluded. 
Treatment
Treatment consisted of six cycles of standard R-CHOP every 3
weeks plus lenalidomide 15 mg orally on day 1-14 (R2CHOP;
Online Supplementary Table S1), followed by two additional 
rituximab administrations. 
Prophylactic intrathecal methotrexate or cytarabine (≥4 admi-
nistrations), pegfilgrastim, venous thromboembolism prophylaxis
(with aspirin or low-molecular-weight-heparin), and Pneumocystis
prophylaxis were mandatory. 
Safety assessments
Adverse events were graded according to National Cancer
Institute Common Terminology Criteria for Adverse Events (AE),
version 4.03. AE grade 1 were not reported.
Study overview
This multicenter, phase II study was designed by investigators
of HOVON and was approved by the medical ethics committee of
the Amsterdam UMC. All patients provided written informed
consent. The trial was conducted in accordance with the
Declaration of Helsinki and Good Clinical Practice guidelines. An
independent data and safety monitoring board conducted a
review during the planned interim analysis. 
Endpoints
The primary endpoint of the study was CMR on EOT PET-CT
scan as determined by central review plus EOT bone marrow
(BM) examination in case of BM localization at diagnosis. In case
a BM examination was not repeated at EOT in patients with base-
line BM localization and the EOT-PET scan showed no BM uptake
localization, the response was classified as CMR (based on recent
findings that CMR on PET-CT has a high negative predictive value
for BM localization).23,24 
Secondary endpoints were: OS defined as time from registra-
tion to death; DFS defined as time from achievement of first CMR
on protocol until relapse or death whichever comes first; EFS
defined as the time from registration to lack of CMR on EOT-PET-
CT, relapse or death; and positive predictive value (PPV) and 
negative predictive value (NPV) of iPET-CT for EOT result.
Statistical analyses
An optimal Simon two-stage design was used with a response
rate of 45% as the null hypothesis, and 60% as the alternative
hypothesis. With a statistical significance level of 5% and a power
of 80%, the required number of patients was 77, with an interim
analysis for futility involving the first 26 included patients. In order
to overcome dropouts due to ineligibility, 85 patients were
enrolled. All efficacy analyses were restricted to eligible patients,
while safety analyses included all enrolled patients. Data cut-off
was June 28, 2019.
For the clinical protocol, central pathology review, central PET-




From April 2015 to February 2018, 85 patients were
included from 20 hospitals in the Netherlands and
Belgium. Three patients were declared ineligible (two
because the MYC+ status was based on immunohisto-
chemistry and not on FISH and one because of a trans-
formed lymphoma), leaving 82 patients for efficacy and 85
patients for safety analyses. 
Baseline patient and disease characteristics are shown in
Table 1. The median age was 63 years (range: 28-82 years).
49 of 81 patients (60%) had a WHO performance status
(PS) of 0; 58 of 71 patients (71%) had stage IV disease, and
42 of 82 patients (51%) had ≥2 extranodal localizations.
The IPI score was high-intermediate and high in 65% of
patients. 
During treatment 12 of 82 patients went off protocol
before completion (progressive disease [n=7], toxicity
[n=2]; pulmonary embolism and diarrhea, other reasons
[n=3]; new diagnosis of colon cancer, patient refusal, and
vertebral fracture), see Figure 1.
Pathology review
Diagnostic biopsy samples of all 85 patients were 
available for pathology review. Results of all 82 eligible
patients are summarized in Table 1 and the Online
Supplementary Table S2. A diagnosis of DLBCL according
to the WHO 2008 classification was confirmed in 65 of 82
patients (79%) and BCL-U in 12 of 82 patients (15%) and
morphology was indecisive between DLBCL and BCL-U
in 5 of 82 patients (6%). For classification according to the
WHO classification 2017 see the Online Supplementary
Table S2.
In 81 of 82 patients MYC rearrangement was confirmed at
central review. Based on the intention to treat principle, the
one patient in whom MYC rearrangement could not be con-
firmed was included in all analyses. In 9 of 82 cases, insuffi-
cient material was available to perform additional BCL2 and
BCL6 rearrangement. In 73 of 82 cases, data on BCL2 and
BCL6 rearrangement were available: 20 of 82 (26%) had a
single MYC rearrangement (SH); 44 of 82 (54%) had DH
lymphoma (31 patients had MYC/BCL2 rearrangements and
13 patients MYC/BCL6 rearrangements), and 9 of 82 (11%)
had all three rearrangements (TH). 
COO classification using a standard Hans algorithm
showed GCB phenotype in 63 of 71 (89%) and non-GCB
phenotype in 8 of 71 (11%). Lymph2Cx classification was
performed in 38 cases showing GCB-subtype in 29 of 38
patients (76%), ABC-subtype in 7 of 38 patients (18%),
and intermediate subtype in 2 of 38 patients (5%). Out of
the 24 DH of TH patients, 21 showed GCB-subtype and 3
ABC-subtype. Out of the 12 SH patients, 8 showed 
GCB-subtype and 4 ABC-subtype.
Treatment
Most patients (n=68) started with lenalidomide in the
second cycle and continued lenalidomide for 14 days after
the sixth cycle of R-CHOP. When MYC FISH results were
available at diagnosis, R2CHOP was started in the first
cycle (n=14) (Figure 1).
Patients received a median (interquartile range [IQR])
dose of the planned drugs in the R-CHOP regimen as fol-
lows: cyclophosphamide 99.9% (99.0-101); vincristine
100% (72.5-100); doxorubicin 99.5% (97.7-101); pred-
nisone 100% (100-100); rituximab 98.1 (95.1-100); pegfil-
grastim 100% (100-100). Lenalidomide was given at a
median dose intensity of 100% (range: 85.7-100). 57 of 82
patients (70%) received the planned ≥4 intrathecal pro-
phylactic administrations. 
Primary endpoint: CMR at EOT
At EOT PET-CT, 55 of 82 patients (67%) reached the
primary endpoint of CMR (95% CI:  58-75, P<0.001), 5 of
82 patients (6%) reached a partial metabolic response
(PMR), and 21of 82 patients (26%) had progressive meta-
bolic disease (PMD) (Table 2). 
One patient went off protocol due to toxicity after cycle
5 without EOT PET-CT (response unknown). 
Univariate logistic regression analysis of baseline char-
acteristics (BM localization, WHO performance status,
stage, B symptoms, IPI, number of extranodal sites and
age) did not reveal any significant predictors for reaching
CMR. 
Exploratory descriptive subgroup analyses revealed no
differences between SH and DH/TH patients regarding
achievement of the primary endpoint: CMR rate in both
groups was 70% and 66% respectively (nine patients with
unknown BCL2 and BCL6 rearrangement not included). 
Secondary endpoints: survival analyses
With a median follow-up of 25.4 months (IQR 18.3-
30.3), 1-year OS was 85% (95% CI: 76-91), DFS 77%
(95% CI: 65-85) and EFS 66% (95% CI: 54-75). 2-year esti-
mates for OS, DFS, EFS were and 73% (95% CI: 62-82),
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75% (95% CI: 63-84) and 63% (95% CI: 52-73) respective-
ly (Figure 2A-C). 
Baseline patient characteristics (BM localization, WHO
performance status, stage, B symptoms, IPI, number of
extranodal sites and age) were not significantly predictive
for prolonged OS in a univariate analysis at the 5% 
significance level. 
Univariate regression analyses indicated that SH and
DH/TH patients had comparable EFS and DFS, however
DH/TH patients had a tendency for a higher risk of death
compared to SH patients (Hazard ratio [HR]4.18, P=0.055;
95% CI: 0.97-18.02) (Online Supplentary Figure S1A-C).
Separate analyses of DH MYC/BCL2 and DH MYC/BCL6
and TH in comparison to SH revealed no significant diffe-
rences in OS (Online Supplementary Figure S2A-B).
In univariate analyses with response as time dependent
covariate we found that patients who had achieved CMR
at EOT PET experienced a reduced risk of death compared
to patients who had not achieved CMR (HR 0.1, 95% CI:
0.03–0.33, P<0.001), (Figure 3). EOT PET-CT predicted
relapse within 12 months, with a positive predictive value
(PPV) of 81% and a negative predictive value (NPV) of 93%
(Online Supplementary Table S3A).
In total, 29 patients showed progressive disease (11
without achieving CMR, 18 after achieving CMR [(at inter-
im or EOT PET-CT)] including one patient with a CNS
relapse. 
Safety 
Grade 2, 3 and 4 AE were seen in 27 (32%), 33 (39%) and
14 (16%) of all 85 registered patients respectively (Table 3).
The most common grade 3–4 AE were neutropenia (18%),
infections (14%) and gastrointestinal disorders (14%). Four
patients experienced deep venous thrombosis (grade 2),
and two patients pulmonary embolism (grade 3). Two of
these patients (one with deep venous thrombosis and one
with pulmonary embolism) had not received the mandato-
ry thrombosis prophylaxis (protocol violation). One
patient went off protocol due to grade 3 diarrhea. 
71 serious AE were reported in 36 patients; 66 were due
to hospitalization (42% infections, 26% gastrointestinal
disorders), four to other conditions [two second primary
malignancies, two recurrence of previously diagnosed (>5
year) malignancies]. One patient died during treatment due
to progression. There were no treatment related deaths. 
Observational analysis: predictive value of iPET-CT 
At iPET-CT after three cycles of R2CHOP, 57 of 82
patients (70%) were in CMR; of these 45 of 57 (79%) were
still in CMR and 11 of 57 (19%) showed PMD at EOT PET-
CT, and one missed EOT evaluation (Table 2). 23 of 82
patients (28%) were in PMR at iPET-CT; 10 of 23 (43%) of
these converted to CMR, 4 of 23 (17%) remained in PMR,
9 of 23 (39%) showed PMD at EOT. The PPV of iPET-CT
for predicting EOT PET-CT result was 60% 
(15 of 25), the NPV 79% (45 of 57) (Online Supplementary
Table S3B). 
Discussion
From retrospective series it is clear that first-line 
R-CHOP therapy is not sufficiently effective for patients
with MYC+ LBCL with CR rates of 40-50% and 3-year
OS rates of 35% only.6,8 Intensified chemotherapy regi-
mens such as R-CODOX-M/R-IVAC or autologous stem
cell transplantation have not improved OS, and result in
increased toxicity.5,9-11 
We designed a prospective clinical trial for MYC+ LBCL
patients, in which a time window of one cycle of R-CHOP
was allowed to perform molecular diagnostics. This
approach permitted high risk patients to start treatment
immediately and overcame the bias of inclusion of mainly
M.E.D. Chamuleau et al.
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Table 1. Patient demographics and disease characteristics.
                                                                 N                            %
Patients completed treatment                                  82                                       100
Median age (range) in years                              63 (28-82)
Sex
male                                                                             56                                       68
female                                                                         26                                       32
WHO performance status                                             
0                                                                                    49                                       60
1                                                                                    26                                       32
2                                                                                     5                                        6
3                                                                                     2                                        2
Prior treatment                                                               
no                                                                                 13                                       16
1 course of R-CHOP                                                68                                       83
only corticosteroids                                                  1                                        1
Ann Arbor stage                                                               
II                                                                                   12                                       15
III                                                                                  12                                       15
IV                                                                                  58                                       71
Extranodal localisations                                                
0                                                                                    31                                       38
1                                                                                     9                                        11
≥2                                                                                 42                                       51
LDH> ULN                                                                       
yes                                                                                57                                       70
no                                                                                 20                                       24
unknown                                                                      5                                        6
Bone Marrow involvement                                           
yes                                                                                16                                       20
no                                                                                 44                                       54
not done                                                                     22                                       27
IPI                                                                                       
Low                                                                              12                                       15
Low-intermediate                                                    17                                       21
High-intermediate                                                    32                                       39
High                                                                             21                                       26
Morphology (WHO2008)                                               
DLBCL                                                                         65                                       79
BCL-U                                                                          12                                       15
indecisive between DLBCL or BCL-U                  5                                        6
COO IHC (Hans classification)                                   
GCB subtype                                                             63                                       77
Non-GCB subtype                                                      8                                        10
Not evaluable                                                            11                                       13
COO GEP (Nanostring) n=38                                      
GCB subtype                                                              29                                       76
ABC subtype                                                               7                                        18
Intermediate                                                              2                                        5
FISH analysis
single hit                                                                     20                                       24
double hit                                                                  44                                       54
         MYC+/BCL2+                                                      31*
         MYC+/BCL6+                                                     13**
triple hit                                                                      9                                        11
MYC+ (BCL2 and BCL6                                          9                                        11
status unknown)                                                       
Demographics and disease characteristics of 82 MYC+ LBCL patients treated with
R2CHOP.  LBLC: large B-cell lymphoma; DLBCL: diffuse large B-cell lymphoma; WHO:
World Health Organisation; R-CHOP: rituximab, cyclophosphamide, doxorubicin, vin-
cristine, and prednisolone; FISH: fluorescence in situ hybridization, LDH: lactate dehy-
drogenase, ULN: upper limit of normal; GCB: germinal center B-cell subtype ; COO: cell-
of-origin; IHC: immune-histochemistry; GEP: gene expression profiling; BCL-U; B-cell
lymphoma, unclassifiable, with features intermediate  between DLBCL and Burkitt lym-
phoma. *from 4 of these patients BCL6 status is unknown, **from 1 of these patients
BCL2 status is unknown.  
lower risk patients due to enrolment delays.25 In this trial
we show that the addition of lenalidomide to R-CHOP
resulted in EOT CMR rate of 67% CMR and 2-year sur-
vival rates of 73%, 75%, and 63% for OS, DFS and EFS
respectively. To our knowledge, this is the second
prospective trial especially designed for MYC+ LBCL
patients. Recently, Dunleavy and colleagues reported a
single arm phase II study in which the efficacy of DA-
EPOCH-R for MYC+ LBCL patients was explored.12
Results for EOT CMR and survival rates are largely com-
parable between both approaches with EOT CMR rate of
74%, 4-year OS rates of 77% and EFS of 71% in the study
MYC+ lymphoma treated with R-CHOP + lenalidomide
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Figure 1. Disposition of the patients. Eighty-two patients were included. In 14 patients, MYC fluorescence in situ hybridization (FISH) was performed immediately at
diagnosis, these patients started with R2CHOP (lenalidomide in combination with rituximab cyclophosphamide, doxorubicin, vincristine, and prednisolone) in cycle
1. In 68 patients, MYC results became available during the first cycle of R-CHOP; these patients were registered after the first cycle of R-CHOP and started with
R2CHOP in the second cycle and continued lenalidomide for 14 days after the sixth cycle of R-CHOP. During treatment 13 patients went off protocol (progressive
disease [n=7], toxicity [n=2; pulmonary embolism and diarrhea], other reasons [n=3; new diagnosis of colon cancer, patient refusal, and vertebral fracture]). 
R: rituximab, R2: rituximab + lenalidomide
of Dunleavy. When compared to the trial of Dunleavy, our
patient population was larger (82 vs. 53 patients), compa-
rable in age (median 63 vs. 61 years) but included more
patients with IPI ≥3 (65% vs. 49%) and more patients with
DH/TH (65% vs. 45%). Regarding safety, grade 3/4 infec-
tions were seen in 24% of cycles with DA-EPOCH-R 
versus grade 3 (and no grade 4 infections) in only 2,8 % of
cycles (18 episodes) with R2CHOP. DA-EPOCH-R 
resulted in three treatment related deaths vs. none with
R2CHOP. 
Lenalidomide penetrates the CNS, and thereby may aid
to prevent CNS relapses as has been suggested for non-
germinal center B-cell (GCB) subtype lymphoma patients
treated with R2CHOP.15 Indeed, in this study, which com-
bined lenalidomide and intrathecal prophylaxis, a remar-
kably low rate of CNS relapse at a median follow-up of
25.4 months was seen (n=1). 
Several remarks regarding our study can be made. First,
although correlation CMR at EOT PET-CT with survival in
MYC+ LBCL has been described in a retrospective study,26
one might argue that it is not an ideal primary endpoint.
Given the high FDG-avidity of MYC+ LBCL and the fact
that CMR at EOT PET-CT in our study was highly predic-
tive for DFS (NPV of 93%), we feel that using CMR at EOT
PET-CT as a surrogate endpoint for highly aggressive B-cell
lymphomas such as MYC+ LBCL is justified. 
Second, clinical prognostic markers, including age, stage,
IPI score, as well as COO were not significantly correlated
to CMR on EOT PET-CT and survival, which might be
explained by the inclusion of high risk patients; 65% of our
patients have an IPI score of ≥3, versus only 27% in Ziepert’s
meta-analysis of the value of IPI in the rituximab era.2 
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Table 2. Response rates on interim and EOT PET-CT scan.
                                                           EOT                    CMR                      PMR                     PMD                     unknown§                      total
Interim                                                                                n                             n                            n                                n                                n
CMR                                                                  n                               45                                 0                                11                                    1                                     57
PMR                                                                  n                               10                                 4                                 9                                     0                                     23
PMD                                                                  n                                0                                  1                                 1                                     0                                      2
total                                                                   n                               55                                 5                                21                                    1                                     82
Response rates on interim and EOT PET-CT scan. Correlation of interim and end of treatment (EOT) response rates by centrally reviewed positron emission tomography (PET)-
computer tomography (CT)scan. §One patient was in complete metabolic response (CMR) at interim scan but went off protocol due to toxicity without an EOT scan. PMR: partial
metabolic response, PMD: progressive metabolic disease. 
Figure 2. Survival analyses. (A) Overall survival (OS; time from registration to
death, n=82); (B) disease-free survival (DFS; time from achievement of first
complete metabolic response [CMR] on protocol until relapse or death
whichever comes first, n=69); (C) event-free survival (EFS; defined as the time
from registration to lack of CMR on end of treatment [EOT] positron emission




Furthermore, our patient population included patients
with SH lymphoma (24%) based on previous reports
demonstrating poor prognosis of these patients following
R-CHOP.5,6,8,27 However, in the revised WHO 2017 classifi-
cation, SH is not recognized as a separate entity in con-
trast to DH/TH lymphoma. Recently, Rosenwald et al.
demonstrated that the inferior prognosis of MYC
rearranged patients is largely observed in patients with
DH lymphoma.7 However, SH patients still have a worse
prognosis compared to patients without a MYC rearrange-
ment, although this is not statistically significant when
regarding OS (P=0.077). Our trial was not powered to
study the prognostic impact of SH versus DH/TH in the
R2CHOP setting. 
Finally, we explored the role of iPET-CT scanning as a
tool for early identification of refractory MYC+ LBCL. In
non-selected cases of DLBCL, CMR on iPET-CT after two
to four R-CHOP cycles has a high NPV for 2-year PFS, but
the PPV varies widely.28 In our study, the PPV of iPET-CT
for achievement of CMR on EOT PET-CT was only 60%
and therefore does not support the use of an interim PET-
CT scan as interpreted with the current standard criteria
to identify primary refractory cases treated with R2CHOP. 
In this prospective trial for newly diagnosed MYC+
LBCL patients, we found that administering R2CHOP was
safe, and yielded comparable CMR and survival rates as in
studies applying intensive chemotherapy regimens.
Moreover, R2CHOP can be delivered on an outpatient
MYC+ lymphoma treated with R-CHOP + lenalidomide
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Figure 3. Survival according to end-of-
treatment PET-CT scan result. Patients
who have achieved complete metabolic
response (CMR) at the end of treatment
(EOT) positron emission tomography
(PET)-computer tomography (CT) scan
experienced a reduced risk of death
compared to patients who have not yet
achieved CMR (Hazard ratio [HR] 0.1,
95% Confidence interval [CI]: 0.03–
0.33, P<0.001). Response was simpli-
fied to “CMR” versus “no-CMR”.
Table 3. Adverse events.
                                                                                                                                               grade2                      grade 3                     grade 4
                                                                                                                                            n             %               n            %                n            %
Hematologic
neutropenia                                                                                                                                                1                 1                    5               6                    10              12
febrile neutropenia                                                                                                                                                                       6              7                                       
thrombocytopenia                                                                                                                                     2                 2                    2              2                    4                5
anemia                                                                                                                                                         6                 7                    5              6                                       
Infectious                                                                                                                                                       15               18                  12            14                                      
Vascular disorders 
pulmonary embolism                                                                                                                                                                    2              3                                       
deep venous trombosis                                                                                                                          4                 5                                                                          
superfical thromboflebitis                                                                                                                      4                 5                                                                          
Nervous system disorders (PNP)                                                                                                            25              29                   9             11                                      
Gastrointestinal disorders                                                                                                                        17              20                  12            14                                      
Hepatobiliary disorders (ALT, AST increased)                                                                                      5                6                    1              1                    2                2
General disorder                                                                                                                                          11               13                   5              6                    1                1
Any*                                                                                                                                                                  27               32                  33            39                  14              16
Adverse events Adverse events (AE) were graded per patient (maximum grade per cycle) according to National Cancer Institute Common Terminology Criteria for AE. AE events
grade 1 were not reported. *In this row each patient is counted only once with the highest grade AE experienced. PNP: polyneuropathy, ALT: alanine transaminase; AST: aspartate
transaminase. 
basis in contrast to Burkitt schemes and is easier to deliver
than DA-EPOCH-R, since it does not require placement of
a central line. These findings offer new prospects for
MYC+ LBCL patients and warrant comparison in prospec-
tive randomized trials.
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